-
1
-
-
0027495285
-
Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones
-
Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 1993;70:357-62
-
(1993)
Br Heart J
, vol.70
, pp. 357-362
-
-
Anand, I.S.1
Chandrashekhar, Y.2
Ferrari, R.3
-
2
-
-
9144264827
-
Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
-
Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19(1):121-32
-
(2004)
Nephrol Dial Transplant
, vol.19
, Issue.1
, pp. 121-132
-
-
Locatelli, F.1
Pisoni, R.L.2
Combe, C.3
-
3
-
-
29244456140
-
Evidence-based systematic literature review of hemoglobin/ hematocrit and all-cause mortality in dialysis patients
-
Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/ hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006;47(1):24-36
-
(2006)
Am J Kidney Dis
, vol.47
, Issue.1
, pp. 24-36
-
-
Volkova, N.1
Arab, L.2
-
5
-
-
33750983605
-
Correction of anemia with epoetin alfa in chronic kidney disease
-
Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;335:2085-98
-
(2006)
N Engl J Med
, vol.335
, pp. 2085-2098
-
-
Singh, A.K.1
Szczech, L.2
Tang, K.L.3
-
6
-
-
33751002326
-
Normalization of hemoglobin level in patients with chronic kidney disease and anemia
-
Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;335:2071-84
-
(2006)
N Engl J Med
, vol.335
, pp. 2071-2084
-
-
Drueke, T.B.1
Locatelli, F.2
Clyne, N.3
-
7
-
-
34548046760
-
KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease, 2007 update of hemoglobin target
-
KDOQI
-
KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease, 2007 update of hemoglobin target. Am J Kidney Dis 2007;50(3):471-530
-
Am J Kidney Dis 2007
, vol.50
, Issue.3
, pp. 471-530
-
-
-
8
-
-
84903837988
-
Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care
-
Locatelli F, Del Vecchio L. Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care. Nephrol Dial Transplant 2014;29(7):1391-8
-
(2014)
Nephrol Dial Transplant
, vol.29
, Issue.7
, pp. 1391-1398
-
-
Locatelli, F.1
Del Vecchio, L.2
-
9
-
-
70949108082
-
TREAT investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
-
Pfeffer MA, Burdmann EA, Chen CY, et al. TREAT investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
-
(2009)
N Engl J Med
, vol.361
, pp. 2019-2032
-
-
Pfeffer, M.A.1
Burdmann, E.A.2
Chen, C.Y.3
-
10
-
-
84155164794
-
TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: The trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience
-
Skali H, Parving HH, Parfrey PS, et al. TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 2011; 124(25):2903-8
-
(2011)
Circulation
, vol.124
, Issue.25
, pp. 2903-2908
-
-
Skali, H.1
Parving, H.H.2
Parfrey, P.S.3
-
11
-
-
77956255701
-
Anaemia Working Group of European Renal Best Practice (ERBP. Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study
-
Locatelli F, Aljama P, Canaud B, et al. Anaemia Working Group of European Renal Best Practice (ERBP. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010;25(9): 2846-50
-
(2010)
Nephrol Dial Transplant
, vol.25
, Issue.9
, pp. 2846-2850
-
-
Locatelli, F.1
Aljama, P.2
Canaud, B.3
-
12
-
-
84867506589
-
KDIGO clinical practice guideline for anemia in chronic kidney disease
-
KDIGO
-
KDIGO. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012;2(4):279-335
-
(2012)
Kidney Int
, vol.2
, Issue.4
, pp. 279-335
-
-
-
13
-
-
84879836673
-
ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement
-
Locatelli F, Bárány P, Covic A, et al. ERA-EDTA ERBP Advisory Board. Kidney Disease: improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013;28(6): 1346-59
-
(2013)
Nephrol Dial Transplant
, vol.28
, Issue.6
, pp. 1346-1359
-
-
Locatelli, F.1
Bárány, P.2
Covic, A.3
-
14
-
-
84886727039
-
KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
-
Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013;62(5):849-59
-
(2013)
Am J Kidney Dis
, vol.62
, Issue.5
, pp. 849-859
-
-
Kliger, A.S.1
Foley, R.N.2
Goldfarb, D.S.3
-
15
-
-
84886718491
-
Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD
-
Moist LM, Troyanov S, White CT, et al. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013;62(5):860-73
-
(2013)
Am J Kidney Dis
, vol.62
, Issue.5
, pp. 860-873
-
-
Moist, L.M.1
Troyanov, S.2
White, C.T.3
-
16
-
-
77749282884
-
Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?
-
Stancu S, Barsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010;5:409-16
-
(2010)
Clin J Am Soc Nephrol
, vol.5
, pp. 409-416
-
-
Stancu, S.1
Barsan, L.2
Stanciu, A.3
Mircescu, G.4
-
17
-
-
77949559450
-
Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD
-
Stancu S, Stanciu A, Zugravu A, et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 2010;55(4):639-47
-
(2010)
Am J Kidney Dis
, vol.55
, Issue.4
, pp. 639-647
-
-
Stancu, S.1
Stanciu, A.2
Zugravu, A.3
-
18
-
-
33947212276
-
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients Response to IV Iron with Elevated Ferritin (DRIVE) Study
-
DRIVE Study Group
-
Coyne DW, Kapoian T, Suki W, et al. DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18(3):975-84
-
(2007)
J Am Soc Nephrol
, vol.18
, Issue.3
, pp. 975-984
-
-
Coyne, D.W.1
Kapoian, T.2
Suki, W.3
-
19
-
-
39049101651
-
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin
-
Kapoian T, OMara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19(2):372-9
-
(2008)
J Am Soc Nephrol
, vol.19
, Issue.2
, pp. 372-379
-
-
Kapoian, T.1
Omara, N.B.2
Singh, A.K.3
-
20
-
-
84864286737
-
Hemodialysis-associated hemosiderosis in the era of erythropoiesis- stimulating agents: A MRI study
-
Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-associated Hemosiderosis in the Era of Erythropoiesis-stimulating Agents: a MRI Study. Am J Med 2012; 125(10):991-9
-
(2012)
Am J Med
, vol.125
, Issue.10
, pp. 991-999
-
-
Rostoker, G.1
Griuncelli, M.2
Loridon, C.3
-
21
-
-
84893662996
-
Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis
-
Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol 2014;39(2): 130-41
-
(2014)
Am J Nephrol
, vol.39
, Issue.2
, pp. 130-141
-
-
Susantitaphong, P.1
Alqahtani, F.2
Jaber, B.L.3
-
22
-
-
84861902546
-
Effects of intravenous iron on mononuclear cells during the haemodialysis session
-
Martin-Malo A, Merino A, Carracedo J, et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012; 27(6):2465-71
-
(2012)
Nephrol Dial Transplant
, vol.27
, Issue.6
, pp. 2465-2471
-
-
Martin-Malo, A.1
Merino, A.2
Carracedo, J.3
-
23
-
-
84867024839
-
The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients
-
Kumbasar A, Gursu M, Kaya C, et al. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients. J Nephrol 2012;25(5):825-32
-
(2012)
J Nephrol
, vol.25
, Issue.5
, pp. 825-832
-
-
Kumbasar, A.1
Gursu, M.2
Kaya, C.3
-
24
-
-
84895731035
-
Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: Does geography matter?
-
De Nicola L, Locatelli F, Conte G, Minutolo R. Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter? Drugs 2014;74(2):159-68
-
(2014)
Drugs
, vol.74
, Issue.2
, pp. 159-168
-
-
De Nicola, L.1
Locatelli, F.2
Conte, G.3
Minutolo, R.4
-
25
-
-
11844249294
-
Inflammation and resistance to treatment with recombinant human erythropoietin
-
Del Vecchio L, Pozzoni P, Andrulli S, Locatelli F. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 2005;15(1): 137-41
-
(2005)
J Ren Nutr
, vol.15
, Issue.1
, pp. 137-141
-
-
Del Vecchio, L.1
Pozzoni, P.2
Andrulli, S.3
Locatelli, F.4
-
26
-
-
60149091852
-
Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients
-
Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009;53(5):823-34
-
(2009)
Am J Kidney Dis
, vol.53
, Issue.5
, pp. 823-834
-
-
Kalantar-Zadeh, K.1
Lee, G.H.2
Miller, J.E.3
-
27
-
-
52049121838
-
Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis
-
Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52(4): 727-36
-
(2008)
Am J Kidney Dis
, vol.52
, Issue.4
, pp. 727-736
-
-
Streja, E.1
Kovesdy, C.P.2
Greenland, S.3
-
28
-
-
50849110807
-
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes
-
Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74(6):791-8
-
(2008)
Kidney Int
, vol.74
, Issue.6
, pp. 791-798
-
-
Szczech, L.A.1
Barnhart, H.X.2
Inrig, J.K.3
-
29
-
-
84878345875
-
Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients
-
Nishio A, Chhatkuli BP, Ma JZ, Kalantari K. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients. Blood Purif 2013;36(1):29-36
-
(2013)
Blood Purif
, vol.36
, Issue.1
, pp. 29-36
-
-
Nishio, A.1
Chhatkuli, B.P.2
Ma, J.Z.3
Kalantari, K.4
-
30
-
-
7444256054
-
Epoetin requirements predict mortality in hemodialysis patients
-
Zhang Y, Thamer M, Stefanik K, et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004;44(5):866-76
-
(2004)
Am J Kidney Dis
, vol.44
, Issue.5
, pp. 866-876
-
-
Zhang, Y.1
Thamer, M.2
Stefanik, K.3
-
31
-
-
84878347460
-
Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease
-
McCullough PA, Barnhart HX, Inrig JK, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 2013;37(6):549-58
-
(2013)
Am J Nephrol
, vol.37
, Issue.6
, pp. 549-558
-
-
McCullough, P.A.1
Barnhart, H.X.2
Inrig, J.K.3
-
32
-
-
77956704796
-
Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes
-
Solomon SD, Uno H, Lewis EF, et al. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363(12):1146-55
-
(2010)
N Engl J Med
, vol.363
, Issue.12
, pp. 1146-1155
-
-
Solomon, S.D.1
Uno, H.2
Lewis, E.F.3
-
33
-
-
84879199103
-
Oxidative effect of several intravenous iron complexes in the rat
-
Bailie GR, Schuler C, Leggett RE, et al. Oxidative effect of several intravenous iron complexes in the rat. Biometals 2013;26(3): 473-8
-
(2013)
Biometals
, vol.26
, Issue.3
, pp. 473-478
-
-
Bailie, G.R.1
Schuler, C.2
Leggett, R.E.3
-
34
-
-
65949107825
-
Ferric carboxymaltose: A review of its use in iron-deficiency anaemia
-
Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009;69(6): 739-56
-
(2009)
Drugs
, vol.69
, Issue.6
, pp. 739-756
-
-
Lyseng-Williamson, K.A.1
Keating, G.M.2
-
35
-
-
77954797927
-
The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: A multi-centre open-label clinical study
-
Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 2010;25(8):2722-30
-
(2010)
Nephrol Dial Transplant
, vol.25
, Issue.8
, pp. 2722-2730
-
-
Covic, A.1
Mircescu, G.2
-
36
-
-
64549090727
-
Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients
-
Grimmelt AC, Cohen CD, Fehr T, et al. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol 2009;71(2):125-9
-
(2009)
Clin Nephrol
, vol.71
, Issue.2
, pp. 125-129
-
-
Grimmelt, A.C.1
Cohen, C.D.2
Fehr, T.3
-
37
-
-
84889607936
-
Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial
-
[Epub ahead of print]
-
Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant 2013. [Epub ahead of print]
-
(2013)
Nephrol Dial Transplant
-
-
Onken, J.E.1
Bregman, D.B.2
Harrington, R.A.3
-
38
-
-
84881241741
-
Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women
-
Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013;28(8):1793-803
-
(2013)
J Bone Miner Res
, vol.28
, Issue.8
, pp. 1793-1803
-
-
Wolf, M.1
Koch, T.A.2
Bregman, D.B.3
-
39
-
-
49649099818
-
Ferumoxytol for treating iron deficiency anemia in CKD
-
Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19(8):1599-605
-
(2008)
J Am Soc Nephrol
, vol.19
, Issue.8
, pp. 1599-1605
-
-
Spinowitz, B.S.1
Kausz, A.T.2
Baptista, J.3
-
40
-
-
66849104249
-
Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients
-
Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009;4(2): 386-93
-
(2009)
Clin J Am Soc Nephrol
, vol.4
, Issue.2
, pp. 386-393
-
-
Provenzano, R.1
Schiller, B.2
Rao, M.3
-
41
-
-
54149119169
-
Safety of ferumoxytol in patients with anemia and CKD
-
Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008;52(5):907-15
-
(2008)
Am J Kidney Dis
, vol.52
, Issue.5
, pp. 907-915
-
-
Singh, A.1
Patel, T.2
Hertel, J.3
-
42
-
-
84904054374
-
A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD
-
[Epub ahead of print]
-
Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014. [Epub ahead of print]
-
(2014)
Clin J Am Soc Nephrol
-
-
Macdougall, I.C.1
Strauss, W.E.2
McLaughlin, J.3
-
44
-
-
77956470416
-
Hepcidin and iron metabolism: From laboratory to clinical implications
-
Franchini M, Montagnana M, Lippi G. Hepcidin and iron metabolism: from laboratory to clinical implications. Clin Chim Acta 2010;411(21-22):1565-9
-
(2010)
Clin Chim Acta
, vol.411
, Issue.21-22
, pp. 1565-1569
-
-
Franchini, M.1
Montagnana, M.2
Lippi, G.3
-
45
-
-
84904329975
-
Liposomial iron: A new proposal for the treatment of anaemia in chronic kidney disease
-
Visciano B, Nazzaro P, Tarantino G, et al. Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease. G Ital Nefrol 2013;30:5
-
(2013)
G Ital Nefrol
, vol.30
, pp. 5
-
-
Visciano, B.1
Nazzaro, P.2
Tarantino, G.3
-
46
-
-
0033800008
-
Clinical studies of HIP: An oral heme-iron product
-
Seligman PA, Moore GM, Schleicher RB. Clinical studies of HIP: an oral heme-iron product. Nutr Res 2000;20:1279-86
-
(2000)
Nutr Res
, vol.20
, pp. 1279-1286
-
-
Seligman, P.A.1
Moore, G.M.2
Schleicher, R.B.3
-
47
-
-
84869454209
-
A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial
-
Barraclough KA, Brown F, Hawley CM, et al. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. Nephrol Dial Transplant 2012;27(11):4146-53
-
(2012)
Nephrol Dial Transplant
, vol.27
, Issue.11
, pp. 4146-4153
-
-
Barraclough, K.A.1
Brown, F.2
Hawley, C.M.3
-
48
-
-
84875075938
-
Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: A randomized controlled trial
-
Nagaraju SP, Cohn A, Akbari A, et al. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrol 2013;14:64
-
(2013)
BMC Nephrol
, vol.14
, pp. 64
-
-
Nagaraju, S.P.1
Cohn, A.2
Akbari, A.3
-
49
-
-
84868605052
-
Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: Results of a randomized, double-blind, placebo-controlled trial
-
Yokoyama K, Hirakata H, Akiba T, et al. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 2012;36(5):478-87
-
(2012)
Am J Nephrol
, vol.36
, Issue.5
, pp. 478-487
-
-
Yokoyama, K.1
Hirakata, H.2
Akiba, T.3
-
50
-
-
84875035936
-
Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients
-
Wüthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013;8(2): 280-9
-
(2013)
Clin J Am Soc Nephrol
, vol.8
, Issue.2
, pp. 280-289
-
-
Wüthrich, R.P.1
Chonchol, M.2
Covic, A.3
-
51
-
-
84880399741
-
PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats
-
Phan O, Maillard M, Peregaux C, et al. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats. J Pharmacol Exp Ther 2013;346(2):281-9
-
(2013)
J Pharmacol Exp Ther
, vol.346
, Issue.2
, pp. 281-289
-
-
Phan, O.1
Maillard, M.2
Peregaux, C.3
-
52
-
-
84875681406
-
Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification
-
Iida A, Kemmochi Y, Kakimoto K, et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol 2013;37(4): 346-58
-
(2013)
Am J Nephrol
, vol.37
, Issue.4
, pp. 346-358
-
-
Iida, A.1
Kemmochi, Y.2
Kakimoto, K.3
-
53
-
-
0037440420
-
Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family
-
Maguer-Satta V, Bartholin L, Jeanpierre S, et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res 2003;282:110-20
-
(2003)
Exp Cell Res
, vol.282
, pp. 110-120
-
-
Maguer-Satta, V.1
Bartholin, L.2
Jeanpierre, S.3
-
54
-
-
77950533566
-
A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys
-
Lotinun S, Pearsall RS, Davies MV, et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010;46: 1082-8
-
(2010)
Bone
, vol.46
, pp. 1082-1088
-
-
Lotinun, S.1
Pearsall, R.S.2
Davies, M.V.3
-
55
-
-
78649364332
-
Hypoxia-inducible factors and the response to hypoxic stress
-
Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010;40(2): 294-309
-
(2010)
Mol Cell
, vol.40
, Issue.2
, pp. 294-309
-
-
Majmundar, A.J.1
Wong, W.J.2
Simon, M.C.3
-
58
-
-
84887011365
-
FG-4592, an oral hypoxia-inducible factor propyl hydroxylase inhibitor, corrects anemia without iron supplementation in incident dialysis patients
-
Abstract
-
Besarab A, Chernyavskaya EN, Motylev I, et al. FG-4592, an oral hypoxia-inducible factor propyl hydroxylase inhibitor, corrects anemia without iron supplementation in incident dialysis patients. J Am Soc Nephrol 2012;23:21A; Abstract
-
(2012)
J Am Soc Nephrol
, vol.23
-
-
Besarab, A.1
Chernyavskaya, E.N.2
Motylev, I.3
-
59
-
-
84898714524
-
Hypoxia inducing factor propyl hydroxylase inhibitor FG-4592 corrects anemia in peritoneal dialysis
-
Abstract
-
Besarab A, Tak Mao Chan D, Dua SL, et al. Hypoxia inducing factor propyl hydroxylase inhibitor FG-4592 corrects anemia in peritoneal dialysis. J Am Soc Nephrol 2013;24:91A; Abstract
-
(2013)
J Am Soc Nephrol
, vol.24
-
-
Besarab, A.1
Tak Mao Chan, D.2
Dua, S.L.3
-
60
-
-
84904359493
-
First-in-man study with BAY 85-3934 - A new oral selective HIF-PH inhibitor for the treatment of oral anemia
-
Abstract
-
Boettcher MF, Lentini S, Kaiser A, et al. First-in-man study with BAY 85-3934 - a new oral selective HIF-PH inhibitor for the treatment of oral anemia. J Am Soc Nephrol 2013;24:347a; Abstract
-
(2013)
J Am Soc Nephrol
, vol.24
-
-
Boettcher, M.F.1
Lentini, S.2
Kaiser, A.3
-
61
-
-
79551583056
-
Hepcidin and disorders of iron metabolism
-
Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347-60
-
(2011)
Annu Rev Med
, vol.62
, pp. 347-360
-
-
Ganz, T.1
Nemeth, E.2
-
62
-
-
84888325289
-
The DOPPS practice monitor for U.S. Dialysis care: Update on trends in anemia management 2 years into the bundle
-
Fuller DS, Pisoni RL, Bieber BA, et al. The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis 2013;62(6):1213-16
-
(2013)
Am J Kidney Dis
, vol.62
, Issue.6
, pp. 1213-1216
-
-
Fuller, D.S.1
Pisoni, R.L.2
Bieber, B.A.3
-
63
-
-
1342301446
-
Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients
-
Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004;65(3):1091-8
-
(2004)
Kidney Int
, vol.65
, Issue.3
, pp. 1091-1098
-
-
Canavese, C.1
Bergamo, D.2
Ciccone, G.3
-
64
-
-
84898903594
-
Angiogenesis in cancer - General pathways and their therapeutic implications
-
Dimova I, Popivanov G, Djonov V. Angiogenesis in cancer - general pathways and their therapeutic implications. J Buon 2014;19(1):15-21
-
(2014)
J Buon
, vol.19
, Issue.1
, pp. 15-21
-
-
Dimova, I.1
Popivanov, G.2
Djonov, V.3
-
65
-
-
84890104909
-
Anti-vascular endothelial growth factor therapy for diabetic macular edema
-
Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013;4(6):151-69
-
(2013)
Ther Adv Endocrinol Metab
, vol.4
, Issue.6
, pp. 151-169
-
-
Boyer, D.S.1
Hopkins, J.J.2
Sorof, J.3
Ehrlich, J.S.4
-
66
-
-
84904366091
-
-
Akebia Meets Primary Endpoint in Phase 2 Study of Once-Daily, [Last accessed 15 October 2013]
-
Akebia Meets Primary Endpoint in Phase 2 Study of Once-Daily, Oral Anemia Treatment, AKB-6548. Available from: www.businesswire.com/news/home/ 20120405005347/en/Akebia-Meets-Primary- Endpoint-Phase-2-Study [Last accessed 15 October 2013]
-
Oral Anemia Treatment, AKB-6548
-
-
-
67
-
-
84878080290
-
Patient independence in chronic kidney disease and anaemia: Implications of the 2012 KDIGO guideline
-
Bennett L. Patient independence in chronic kidney disease and anaemia: implications of the 2012 KDIGO guideline. J Ren Care 2013;39(2):108-17
-
(2013)
J Ren Care
, vol.39
, Issue.2
, pp. 108-117
-
-
Bennett, L.1
-
68
-
-
84888325289
-
The DOPPS practice monitor for U.S. Dialysis care: Update on trends in anemia management 2 years into the bundle
-
Fuller DS, Pisoni RL, Bieber BA, et al. The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis 2013;62(6):1213-16
-
(2013)
Am J Kidney Dis
, vol.62
, Issue.6
, pp. 1213-1216
-
-
Fuller, D.S.1
Pisoni, R.L.2
Bieber, B.A.3
-
69
-
-
84855436897
-
Safety immunogenicity and efficacy of subcutaneous biosimilar epoetin-A (HX575) in non-dialysis patients with renal anemia: A multi-center randomized double-blind study
-
Haag-Weber M, Eckardt KU, Hörl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-a (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012;77(1):8-17
-
(2012)
Clin Nephrol
, vol.77
, Issue.1
, pp. 8-17
-
-
Haag-Weber, M.1
Eckardt, K.U.2
Hörl, W.H.3
-
70
-
-
84878879825
-
Peginesatide as a new approach for treating anemia of CKD patient: Is it like a falling star?
-
Locatelli F, Del Vecchio L. Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star? Expert Opin Pharmacother 2013;14(10):1277-80
-
(2013)
Expert Opin Pharmacother
, vol.14
, Issue.10
, pp. 1277-1280
-
-
Locatelli, F.1
Del Vecchio, L.2
-
71
-
-
84904334002
-
-
European medicines agency [Last accessed 26 February 2014]
-
European medicines agency. Available from: www.ema.europa.eu/ema/index. jsp? curl=pages/news-and-events/news/2013/06/ news-detail-001833. jsp&mid=WC0b01ac058004d5c1 [Last accessed 26 February 2014]
-
-
-
-
72
-
-
84904288562
-
-
FDA [Last accessed 31 March 2014]
-
FDA. Available from: www.fda.gov/Safety/ MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ ucm340895.htm [Last accessed 31 March 2014]
-
-
-
-
73
-
-
84904349123
-
-
Clinical trials [Last accessed 31 March 2014]
-
Clinical trials. Available from: http:// clinicaltrials.gov/ct2/results? term=AKB-6548 +Search=Search [Last accessed 31 March 2014]
-
-
-
-
74
-
-
84904315316
-
-
Akebia Meets Primary Endpoint in Phase 2 Study of Once-Daily, Oral Anemia Treatment, AKB-6548 [Last accessed 31 March 2014]
-
Akebia Meets Primary Endpoint in Phase 2 Study of Once-Daily, Oral Anemia Treatment, AKB-6548. Available at www. businesswire.com/news/home/ 20120405005347/en/Akebia-Meets-Primary- Endpoint-Phase-2-Study [Last accessed 31 March 2014]
-
-
-
-
75
-
-
84904324779
-
-
GSK [Last accessed 31 March 2014]
-
GSK. Available at www.gskclinicalstudyregister. com/result-comp-list. jsp?compound=GSK1278863 [Last accessed 31 March 2014]
-
-
-
|